Significance of EASI-75 Response Rates in Patients with Skin of Color on Lebrikizumab

Published Date: 27 Jun 2025

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot